-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s IONIS-FB-LRx
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's IONIS-FB-LRx report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eplontersen Sodium in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eplontersen Sodium in Familial Amyloid Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eplontersen Sodium in Familial Amyloid Cardiomyopathy Drug Details: Eplontersen sodium...
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s IONIS-FB-LRx
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's IONIS-FB-LRx report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lysergic Acid Diethylamide in Anxiety Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lysergic Acid Diethylamide in Anxiety Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lysergic Acid Diethylamide in Anxiety Disorders Drug Details: Lysergic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Melanoma Drug Details: Vobramitamab duocarmazine (MGC-018) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Ovarian Cancer Drug Details: Vobramitamab duocarmazine (MGC-018)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IONIS-FB-LRx in Geographic Atrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IONIS-FB-LRx in Geographic Atrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IONIS-FB-LRx in Geographic AtrophyDrug Details:IONIS-FB-LRx is under development for the treatment of geographic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IONIS-FB-LRx in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IONIS-FB-LRx in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IONIS-FB-LRx in IgA Nephropathy (Berger's Disease) Drug Details:IONIS-FB-LRx is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-2B530 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-2B530 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-2B530 in Non-Small Cell Lung Cancer Drug Details: A-2B530...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STT-003 in Head And Neck Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Head And Neck Cancer Drug Details: STT-003 is under development for the treatment...